Palatin Technologies, Inc. (AMEX: PTN), a biopharmaceutical company, has dedicated their efforts to developing peptide, peptide mimetic and small molecule agonist compounds. Their primary focus is on melanocortin and natriuretic peptide receptor systems, including acute hospital care products in the cardiovascular field, for treating congestive heart failure, hard-to-control hypertension as well as cardiac surgery organ protection. For further information, visit the Company’s web site at www.palatin.com.
- 18 years ago
QualityStocks
Palatin Technologies, Inc. (AMEX: PTN)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones
Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel-based cartilage regeneration technology toward key clinical, regulatory…
-
Wrap Technologies Inc. (NASDAQ: WRAP) Positions Non-Lethal Innovation at the Center of Public Safety Reform
WRAP offerings illustrate a broader industry trend toward building connected ecosystems rather than standalone products.…
-
Brownfield Gold Projects Could Hold an Edge in Today’s Permitting Environment
Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.…